Micromet

In 2003, CAT granted Micromet a patent licence for the development and commercialisation of Micromet's human monoclonal antibody drug candidate MT201 (adecatumumab) against the epithelial tumour target Ep-CAM. In 2004, Micromet and Serono signed an exclusive collaboration and licence agreement for the development and commercialisation of MT201 which is currently being tested in two multi-centre Phase II clinical trials and a Phase I trial in combination with Taxotere^® (docetaxel). CAT will receive milestone and royalty payments on human antibody therapeutics successfully developed against the Ep-CAM target by Micromet and its partners.